Gamal Ghoniem,*, Jacques Corcos, Craig Comiter, Peter Bernhard, O. Lenaine Westney and Sender Herschorn
|
|
- Tobias Carter
- 6 years ago
- Views:
Transcription
1 Cross-Linked Polydimethylsiloxane Injection for Female Stress Urinary Incontinence: Results of a Multicenter, Randomized, Controlled, Single-Blind Study Gamal Ghoniem,*, Jacques Corcos, Craig Comiter, Peter Bernhard, O. Lenaine Westney and Sender Herschorn From the Cleveland Clinic Florida (GG), Weston, Florida, Urology Associates (PB), Minneapolis, Minnesota, McGill Urology Associates (JC), Montreal, Quebec and University of Toronto (SH), Toronto, Ontario, Canada, Stanford University Medical School (CC), Stanford, California, and University of Texas (OLW), Houston, Texas Abbreviations and Acronyms I-QOL Urinary Incontinence Quality of Life Scale ISD intrinsic sphincter injury SUI stress urinary incontinence UBA urethral bulking agent Submitted for publication May 19, Study received institutional review board approval at each participating site. * Correspondence: Section of Voiding Dysfunction, Female Urology and Reconstruction, Cleveland Clinic Florida, (telephone: ; FAX: ; ghonieg@ ccf.org). Financial interest and/or other relationship with Astellas, Coloplast, Uroplasty and Bulkamid. Financial interest and/or other relationship with Johnson & Johnson, Astellas, Purdue, Triton and Allergan. Financial interest and/or other relationship with Coloplast and Astellas. Financial interest and/or other relationship with American Medical Systems. Financial interest and/or other relationship with Pfizer, Astellas, Johnson & Johnson, Allergan and Lilly. Purpose: In a pivotal trial we evaluated the effectiveness and safety of Macroplastique as minimally invasive endoscopic treatment for female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Materials and Methods: A total of 247 females with intrinsic sphincter deficiency were randomized 1:1 and treated with a transurethral injection of Macroplastique or Contigen. The latter group served as the control. Repeat treatment was allowed after the 3-month followup. Effectiveness was determined 12 months after the last treatment using Stamey grade, pad weight and Urinary Incontinence Quality of Life Scale scores. Safety assessment was recorded throughout the study. Results: After 12 patients were excluded from study 122 patients received Macroplastique injection and 125 received Contigen injection. Mean patient age was 61 years and the average history of incontinence was 11.2 years. Of the patients 24% had undergone prior incontinence surgery. At 12 months after treatment 61.5% of patients who received Macroplastique and 48% of controls had improved 1 Stamey grade. In the Macroplastique group the dry/cure rate was 36.9% compared to 24.8% in the control group (p 0.05). In the Macroplastique and control groups the 1-hour pad weight decrease was 25.4 and 22.8 ml from baseline (p 0.64), and the mean improvement in Urinary Incontinence Quality of Life Scale score was 28.7 and 26.4 (p 0.49), respectively. Conclusions: Macroplastique injection was statistically more effective than Contigen for stress urinary incontinence primarily due to intrinsic sphincter deficiency with a 12.1% cure rate difference. Macroplastique can be administered on an outpatient basis. It should be considered a primary or secondary treatment option for stress urinary incontinence. Key Words: urethra; urinary incontinence, stress; injections; prostheses and implants; female STRESS urinary incontinence is a debilitating and dynamic condition affecting millions of individuals worldwide. In the United States alone SUI is the most prevalent form of incontinence in women and it has a negative impact on almost 30% of women older than 18 years (approximately 31 million). 1 This is especially relevant to the baby boomer generation in the United States since prevalence as well as severity increases with age /09/ /0 Vol. 181, , January 2009 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2009 by AMERICAN UROLOGICAL ASSOCIATION DOI: /j.juro
2 CROSS-LINKED POLYDIMETHYLSILOXANE INJECTION FOR URINARY INCONTINENCE 205 Of women with stress incontinence 10% who have severe incontinence are 25 to 44 years old compared with 15% of women who are 45 to 59 and 33% who are older than 60 years. Furthermore, in women with urge incontinence the corresponding rates are 8%, 18% and 45%, and in those with mixed incontinence the rates are 19%, 33% and 53%, respectively. 3 Common treatment options for SUI include behavioral modification, pelvic muscle strengthening such as Kegel exercises or biofeedback, sling placement surgery and UBAs. The latter have been used successfully for many years, including autologous fat, collagen and polytetrafluoroethylene. 4 However, these early treatment options posed problems of reabsorption, allergic reaction or hypersensitivity and migration. 4 In recent years additional materials have been introduced as UBAs for SUI, including polydimethylsiloxane elastomer, dextranomer/hyaluronic acid copolymer, zirconium carbon coated beads and calcium hydroxylapatite. One such product is the Macroplastique implant, an injectable soft tissue UBA. Since 1991, Macroplastique has been used outside the United States for female and male urinary incontinence, and vesicoureteral reflux. 5,6 Macroplastique consists of a soft, flexible, highly textured implant of fully cross-linked polydimethylsiloxane (solid silicone elastomer) with a mean diameter of 140 m that is suspended in an inert bio-excretable polyvinylpyrrolidone carrier. This product is nonallergenic, causes a minimal inflammatory reaction, is ready to use and effective, and has not been shown to migrate. 7 Upon implantation the elastomer implant is encapsulated in fibrin and remains as a bulking agent, while the carrier gel is absorbed by the reticuloendothelial system and excreted unmetabolized through the kidneys. The fibrous capsule remains stable after formation, which is thought to prevent any subsequent movement or migration. 8 A systematic review of Macroplastique treatment for SUI showed a success rate of between 46% and 88%. 4 However, a lack of large, prospective, randomized trials of sufficiently high methodological quality limits the usefulness of the previously published data. Furthermore, we noted that in the majority of trials sample size was too small to determine any significant differences among the subgroups. Therefore, there is an obvious need for randomized, controlled comparative trials of SUI treatment with UBAs. To our knowledge this study represents the first large, multicenter, randomized trial investigating the long-term safety and effectiveness of Macroplastique compared to the commercially available, collagen-based urethral bulking agent Contigen, which served as the control. MATERIALS AND METHODS Study Design Between November 1999 and February 2003, a total of 260 patients from 12 investigational sites in the United States and Canada were randomized 1:1 to the Macroplastique or Contigen (control) group. Institutional review board approval was obtained locally at each participating site. Patients were blinded to treatment. However, due to the obviously different appearance and handling characteristics of the 2 study materials, it was impossible to blind the treating physicians. This clinical trial was done after obtaining written informed consent from each patient. Patients were recruited through investigational sites, physician referrals, newspaper advertisements and direct patient mailing. Inclusion and Exclusion Criteria Eligibility for inclusion required a diagnosis of SUI primarily due to ISD without improvement with conservative treatments, such as behavior modification (biofeedback) or exercise (Kegel). Additional criteria were a viable mucosal lining and normal bladder capacity. Patients with urinary tract infection, uncontrolled detrusor overactivity, high post-void residual urine volume, high grade pelvic organ prolapse, confounding bladder pathology, pregnancy or morbid obesity were excluded from study. The study involved baseline assessment, treatment and followup at 1, 3, 6 and 12 months. In the 2 arms repeat treatment was allowed after the 3-month followup in all consenting patients who were not cured by the first treatment, at which time the followup visit schedule was reinitiated. Baseline assessment included patient demographics and medical history, 3-day voiding diary, physical examination, cystoscopy, urodynamics with medium fill cystometry and abdominal leak point pressure measurement, I-QOL score and pad weight test. Procedure Macroplastique or Contigen implantation was performed using a transurethral endoscopic procedure with a rigid 12-degree lens cystoscope. Approximately 5 ml were delivered through a 5Fr or 7Fr needle with the patient under local or general anesthesia, occasionally in conjunction with mild sedation. Macroplastique was administered with an injector device. Outcome Measures Incontinence status was measured at baseline and at all followup visits by the investigators using the Stamey incontinence grading and pad weight testing. Stamey grading is a 4 level scale of incontinence severity ranging from 0 continent-dry to 3 total incontinence regardless of activity. Pad weight testing was done using a standardized format measuring urine loss during a 1-hour period following a series of activities outlined by the International Continence Society. 9 Quality of life was measured at baseline and at each followup visit using I-QOL. 10 At each visit patients and investigators subjectively evaluated treatment success as dry, markedly improved, slightly improved or unchanged. Safety was assessed by recording any adverse events.
3 206 CROSS-LINKED POLYDIMETHYLSILOXANE INJECTION FOR URINARY INCONTINENCE Statistical Analysis A required sample size of 208 participants was calculated based on a noninferiority test using the Blackwelder formula ( 0.05, 0.20 and 0.15) and run on PASS 6.0 software (NCSS, Kaysville, Utah). To account for dropouts 260 participants were recruited and 247 underwent implantation as randomized. All analyses were done elsewhere with SAS, version 9.1 using SAS data files. A decrease in baseline I-QOL grade of at least 1 Stamey grade at 12 months indicated improvement and served as the primary efficacy end point. The null hypothesis stated that the difference (Contigen minus Macroplastique) in the proportion of patients showing improvement in incontinence would be greater than 15%. Stamey grade as the primary end point and the 15% differential in the null hypothesis were selected according to the recommendation of the United States Food and Drug Administration, which provided regulatory oversight for this investigational device exemption clinical study. Additional end points were change in pad weight and change in I-QOL from baseline, the proportion of patients who were dry (Stamey grade 0) and the proportion of patients who were markedly improved or dry by subjective report. Analysis of the primary efficacy end point was performed using intent to treat analysis, which included all 247 patients treated per protocol but excluded those who did not receive the randomized treatment. Patients who were lost to followup or otherwise withdrawn were considered treatment failures regardless of any success seen at previous visits and, thus, they were considered evaluable at 12 months. The last treatment carried forward was not used to avoid the potential bias of increased success. The Macroplastique group and Contigen control group were compared with a 2-step approach using the Blackwelder test of noninferiority with a noninferiority margin of 15%. 11 Additionally, the 95% CI for the difference in proportions was compared to 0 for a 1-sided test of significance. The within-subject incontinence grade improvement from baseline was also calculated 12 months after the last treatment in each group and compared to 0 in a 1-sample median test. Subgroup comparisons of the primary efficacy end point were done with a logistic regression model. Additional end points were analyzed by calculating differences and the corresponding 95% CI. Safety assessment, which included all patients treated according to protocol, were recorded throughout the study. The incidence of adverse events is reported as the difference of proportions and the corresponding 95% CI. RESULTS Not treated with Macroplastique n = 8 Randomized n = 260 Not treated with Collagen n = 5 Patient Demographics Of the 260 patients randomized into the study 247, including 122 in the Macroplastique group and 125 in the control group, were treated according to the study protocol (fig. 1). Eight patients in the Macroplastique group and 4 in the control group withdrew prior consent to treatment and 1 who was randomized to the control group received Macroplastique and, thus, was excluded from further analysis. At the 12-month followup, 20 patients with Macroplastique and 31 controls were considered discontinued due to loss to followup, withdrawal for noncompliance or patient request for other treatment. Fol- Intent-totreat Group Macroplastique n = 122 Controls n = 125 Discontinued n = 20 Lost to follow-up (6) Withdrew other treatment (9) Other (5) n = 31 Lost to follow-up (8) Withdrew other treatment (14) Other (9) Completed Study n = 102 n = 94 Figure 1. Study flow diagram
4 CROSS-LINKED POLYDIMETHYLSILOXANE INJECTION FOR URINARY INCONTINENCE 207 Table 1. Patient baseline characteristics Macroplastique Control p Value No. pts Mean SD pt age (t test) Mean SD incontinence history (yrs) (t test) No. previous incontinence procedure (%) 29 (23.8) 30 (24.0) 0.97 (t test) No. hysterectomy (%) 63 (51.6) 65 (52.0) 0.95 (t test) No. Stamey grade (%): I 36 (29.5) 48 (38.4) 0.55 (chi-square test) II 84 (68.9) 69 (55.2) III 2 (1.6) 8 (6.4) 1-Hr pad wt test: No. pts (t test) Mean SD loss (ml) lowup visits at 12 months were completed by 102 patients with Macroplastique and 94 controls. The 2 treatment groups were well balanced relative to demographic variables (table 1). Average age was 61 years, 95% of the women were white and the mean history of urinary incontinence was 11.2 years. Of the women 51.8% had undergone hysterectomy, 72.8% were postmenopausal and 23.9% reported a previous surgical incontinence procedure. The total number of treatments was similar in the 2 groups with 47.5% of patients with Macroplastique and 41.6% of controls receiving a single treatment. In addition, there was no difference in treatment volume between the Macroplastique and control groups (table 2). Efficacy Of all patients treated 61.5% (75 of 122) with Macroplastique and 48% (60 of 125) of controls had an improvement of at least 1 Stamey grade at 12 months, demonstrating that Macroplastique is not inferior to Contigen (p 0.001, table 3). The 95% upper bound for the difference in proportions was less than 0, demonstrating that the Macroplastique group had a significantly improved Stamey grade compared to the control group using a 1-sided test of significance. The 2 groups had a median withinsubject improvement in Stamey grade of 1 and demonstrated significant improvement in Stamey grade at 12 months from baseline (p 0.001, fig. 2). At 12 months the proportion of patients with a Stamey grade of 0 or dry outcome was significantly Table 2. Treatment characteristics Macroplastique Control p Value % Pts with max allowed treatments Mean SD total implant vol (ml): Treatment Treatment Overall higher for Macroplastique than for Contigen ((36.9% vs 24.8%, p 0.05, table 3 and fig. 2). Subject and physician assessments of dry/improvement showed good agreement with similar results. Patient and physician scores of dry/markedly improved for Macroplastique were 77.4% and 80.4% vs 68.1% and 74.4% for controls, respectively (table 3). At 12 months the average SD urine loss was and 5.9 ml 14.4 ml in the Macroplastique and control groups, respectively. This represented an average decrease in urine loss from baseline at ml for Macroplastique compared to ml for Contigen (p 0.64, table 3). Relative to I-QOL, the 2 groups were significantly improved from baseline (p 0.001). Each showed a similar improvement in I-QOL subscales, including avoidance and limiting behavior, psychosocial impacts and social embarrassment, with no difference in improvement between the groups. Overall there was no statistical evidence that the percent of participants with an improvement in Stamey grade or dryness was affected by previous incontinence surgery, as reported at baseline in the Macroplastique and control groups (p 0.58 and 0.65, respectively). Furthermore, there was no statistical evidence of a difference in treatment effect related to age or hormonal status (p 0.69 and 0.75, respectively, table 4). Safety There was no significant difference between the Macroplastique and control groups relative to the number of adverse events experience by patients (59% and 54.4%, respectively, table 5). For purposes of analysis all genitourinary adverse events regardless of timing or investigator designation were considered treatment related during the study course. No serious treatment related adverse events were reported for Macroplastique, while only 1 serious treatment related event (kidney infection) was reported in controls.
5 208 CROSS-LINKED POLYDIMETHYLSILOXANE INJECTION FOR URINARY INCONTINENCE Table 3. Macroplastique and Contigen effectiveness at 12 months Macroplastique Controls p Value No. Stamey grade (%):* (dry) 45 (36.9) 31 (24.8) 0.05 (chi-square test) Improvement 75 (61.5) 60 (48.0) (noninferiority) No. pt assessment (%): (chi-square test) Dry 34 (33.3) 25 (26.6) Improved 45 (44.1) 39 (41.5) Slightly improved 15 (14.7) 19 (20.2) Unchanged 8 (7.8) 11 (11.7) No. physician assessment (%): (chi-square test) Dry 43 (42.2) 32 (34.0) Marked improvement 39 (38.2) 38 (40.4) Slight improvement 14 (13.7) 14 (14.9) Unchanged 6 (5.9) 10 (10.6) Mean SD 1-hr pad wt test (t test) decrease from baseline (ml) Mean SD I-QOL improvement (t test) * On intent to treat analysis with all patients lost to followup at 12 months considered failures. As followed analysis with only patients attending the 12-month followup analyzed. DISCUSSION The results of this study are notable in light of other reports in the published literature of synthetic bulking agents The reported success rate at 1 year in this study was statistically higher for Macroplastique vs the biological control (61% vs 48%, p 0.05). This result is noteworthy, considering that this trial was done in a large, randomized population of patients with statistically similar baseline characteristics. Additionally, the dry rate for Macroplastique at 1 year was statistically higher than the dry rate in the control group (37% vs 25%, p 0.05). Thus, in these respects Macroplastique is the first synthetic bulking agent to clinically demonstrate a greater potential for long-term success compared to biological bulking agents. Finally, Macroplastique was an acceptable treatment in patients with previous surgical therapy for incontinence. Since 23.8% and 24.0% of all randomized patients with Macroplastique and controls had undergone previous surgical Macroplastique Contigen Percentage of Subjects Stamey Improvement Stamey Dry Figure 2. Mean percent of patients improved and cured at 12 months (each p 0.05). Bars indicate 95% CI
6 CROSS-LINKED POLYDIMETHYLSILOXANE INJECTION FOR URINARY INCONTINENCE 209 Table 4. Treatment effect by baseline characteristics No. Pts/Total No. (%) Macroplastique Control Logistic Regression* Age: Younger than /63 (57.1) 27/59 (45.8) or Older 39/59 (66.1) 33/66 (50.0) Premenopausal 15/32 (46.9) 13/35 (37.1) Postmenopausal 59/89 (66.3) 47/90 (52.2) 0.75 Treatment effect defined as percent improved by 1 Stamey grade. * Test for interaction across baseline strata. treatment, there was no significant effect of previous surgery on a successful outcome at 12 months. To our knowledge this study represents the first North American clinical investigation of Macroplastique for SUI. Since 1991, thousands of patients with SUI outside the United States have undergone treatment with Macroplastique. As a textured solid silicone elastomer implant, Macroplastique fulfills the criteria of being nonallergenic, causing minimal inflammatory reaction and having no known implant site migration. Additionally, since silicone is nonresorbable and nondegradable, Macroplastique is a permanent implant capable of providing longterm improvement of SUI. Although silicone materials were subject to adverse public scrutiny in the 1990s due to the use of silicone gels in the breast implant controversy, cured silicone elastomers such as Macroplastique continue to be one of the most widely studied and safe materials used in medical device implants. Silicone elastomers are used in implants such as hydrocephalic shunts, pacemaker and lead wire coatings, and finger joint implants. Silicone elastomer has the advantage that it can be formed into highly textured implants while still maintaining a rubber-like suppleness that may decrease the potential for erosion, which is sometimes seen with more rigid implant materials, making it ideal for UBAs. 15 The primary benefit of UBAs is to provide an effective and minimally invasive primary or secondary treatment option for SUI. Radley et al assessed the effect of previous surgical treatment on the effectiveness of Macroplastique for SUI and found no statistically significant difference. 16 Patients with a fixed urethra have a lower success rate with tape procedures compared to women with urethral hypermobility only. 17 Thus, patients in whom previous surgical or nonsurgical treatment for SUI has failed can be considered candidates for a UBA such as Macroplastique. If sling surgery fails to adequately treat SUI, patients with a residual ISD component to SUI may need addition treatment with a bulking agent. The role of UBAs for SUI has changed since their introduction into the United States market in Once considered a primary treatment option, UBAs are currently used more as a secondary option due to the popularity and reportedly higher effectiveness of sling procedures (80% to 85%). 18 However, sling surgery carries inherent risk, ranging from voiding dysfunction to vaginal extrusion and even urethral erosion. 19,20 UBAs are an attractive primary treatment option in patients with impaired health in whom the increased risks associated with sling procedures outweigh the potential benefits of treatment. Additionally, UBAs are an effective secondary treatment option when incontinence due to urethral hypermobility may have been corrected by a urethral sling Table 5. Adverse events No. Macroplastique (%) No. Control (%) Difference (95% CI) Urinary tract infection (0 365 days after implantation) 29 (23.8) 31 (24.8) 1.0 ( 9.7, 11.7) Dysuria 11 (9.0) 10 (8.0) 1.0 ( 8.0, 5.9) Urgency 11 (9.0) 9 (7.2) 1.8 ( 8.6, 5.0) Frequency 10 (8.2) 12 (9.6) 1.4 ( 5.7, 8.5) Urinary retention 8 (6.6) 4 (3.2) 3.4 ( 8.7, 2.0) Hesitancy 6 (4.9) 8 (6.4) 1.5 ( 4.3, 7.2) Urge incontinence 6 (4.9) 5 (4.0) 0.9 ( 6.1, 4.2) Slowed urine stream 5 (4.1) 10 (8.0) 3.9 ( 2.0, 9.8) Incomplete bladder emptying 5 (4.1) 5 (4.0) 0.1 ( 5.0, 4.8) Transient hematuria 5 (4.1) 5 (4.0) 0.1 ( 5.0, 4.8) Implantation site pain 4 (3.3) 5 (4.0) 0.7 ( 3.9, 5.4) Overactive bladder 3 (2.5) 0 (0.0) 2.5 ( 5.2, 0.3) Yeast infection 3 (2.5) 3 (2.4) 0.1 ( 3.9, 3.8) Bladder pain 2 (1.6) 2 (1.6) 0.0 ( 3.2, 3.1) Urine stream change 2 (1.6) 2 (1.6) 0.0 ( 3.2, 3.1) Increased/worsening nocturia 2 (1.6) 1 (0.8) 0.8 ( 3.6, 1.9) Urethral erosion 2 (1.6) 1 (0.8) 0.8 ( 3.6, 1.9) Other, including headache nausea 22 (18.0) 16 (12.8) 5.2 ( 14.2, 3.8) Totals 72/122 (59.0) 68/125 (54.4) 4.6 ( 17.0, 7.7)
7 210 CROSS-LINKED POLYDIMETHYLSILOXANE INJECTION FOR URINARY INCONTINENCE but the patient still experiences some degree of incontinence due to continued ISD. Finally, in our study greater 12-month efficacy would likely have been achieved without protocol limitations to the number of re-treatments (1) or the period for allowing re-treatment (within 4 weeks after the 3-month followup). These restrictions were necessary because of time constraints for study completion. However, in real life circumstances in a community based practice such limitations would likely not have a role. CONCLUSIONS The results of this study demonstrate that Macroplastique is more effective than Contigen for SUI primarily due to ISD based on the observed cure rates and overall improvement in Stamey scores. Other study end points, such as pad weight and quality of life results, favored Macroplastique but were not statistically significant. Macroplastique is a safe, efficacious, minimally invasive injectable silicone material that can be administered on an outpatient basis. It should be considered a primary or secondary treatment option for SUI. ACKNOWLEDGMENTS Statistical analysis was done at The Integra Group, Brooklyn Park, Minnesota. APPENDIX Study Investigators Gamal Ghoniem, Cleveland Clinic Florida, Weston, Florida; Peter Bernhard, Urology Associates, Minneapolis, Minnesota; Jacques Corcos, McGill Urology Associates, Montreal, Quebec and Sender Herschorn, University of Toronto, Toronto, Ontario, Canada; Craig Comiter, University of Arizona, Tucson, Arizona; Kevin Tomera, Alaska Clinical Research Center, Anchorage, Alaska; O. Lenaine Westney, University of Texas, Houston, Texas; Vincent Lucente, Lehigh Valley Hospital, Allentown, Pennsylvania; John Smith, Lahey Center, Burlington, Massachusetts; and Gregory Wahle, Urology of Indiana and John Mulcahy, Indiana University, Indianapolis, Indiana. REFERENCES 1. Fultz NH, Burgio K, Diokno AC, Kinchen KS, Obenchain R and Bump RC: Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003; 189: Hannestad YS, Rortveit G, Sandvik H and Hunskaar S: A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the Country of Nord-Trondelag. J Clin Epidemiol 2000; 53: Prevalence and Treatment Patterns of Pelvic Health Disorders Among U.S. Women. Lewin Group. National Women s Health Resource Center, June Available at org/documents/nwhrc.prevalenceandtreatment PatternsPelvicHealthDisorders.report.pdf. Accessed September 22, Ter Muelen PH, Berghmans LCM and van Kerrebroeck PEV: A systematic review: efficacy of silicone microimplants (Macroplastique ) therapy for stress urinary incontinence in adult women. Eur Urol 2003; 44: Harriss DR, Iacovou JW and Lemberger RJ: Periurethral silicone microimplants (Macroplastique) for the treatment of genuine stress incontinence. Br J Urol 1996; 78: Buckley JF, Azmy AA, Fyfe AB, Scott R, Kirk D, Deane RF et al: Endoscopic correction of vesicoureteric reflux with injectable silicone microparticles. J Urol, suppl., 1993; 149: 259A, abstract Tamanini JT, D Ancona CAL, Tadini V and Netto NR Jr: Macroplastique implantation system for the treatment of female stress urinary incontinence. J Urol 2003; 169: Soliman S and Evans C: Endoscopic Macroplastique injection for the treatment of female stress incontinence: role and efficacy. African J Urol 2001; 7: Abrams P, Blaivas JG, Stanton SL and Andersen JT: The standardization of terminology of lower urinary tract function. International Continence Society Committee on Standardization of Terminology. Scand J Urol Nephrol, suppl., 1988; 114: Bushnell DM, Martin ML, Summers KH, Svihra J, Lionis C and Patrick DL: Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Qual Life Res 2005; 14: Hwang IK and Morikawa T: Design issues in non-inferiority/equivalence trials. Drug Inform J 1999; 33: Kiilholma P and Mäkinen J: Disappointing effect of endoscopic Teflon injection for female stress incontinence. Eur Urol 1991; 20: Stenberg A, Larsson G, Johnson P, Heimer G and Ulmsten U: DiHA Dextran Copolymer, a new biocompatible material for endoscopic treatment of stress incontinent women. Acta Obstet Gynecol Scand 1999; 78: Lightner D, Calvosa C, Andersen R, Klimberg I, Brito CG, Synder J et al: A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. Urology 2001; 58: Hurtado E, McCrery R and Appell R: The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: Radley SC, Chapple CR, Mitsogiannis IC and Glass KS: Transurethral implantation of Macroplastique for the treatment of female stress urinary incontinence secondary to intrinsic sphincter deficiency. Eur Urol 2001; 39: Muller M, Koebele A and Deval B: Determinants of success and recurrence after suburethral free tape procedure for female urinary incontinence. J Gynecol Obstet Biol Reprod 2007; 36: Bullock TL, Ghoniem GM, Klutke CG and Staskin DR: Advances in female stress urinary incontinence: mid-urethral slings. BJU Intl, suppl., 2006; 98: Levin I, Groutz A, Gold R, Pauzner D, Lessing JB and Gordon D: Surgical complications and medium-term outcome results of tension-free vaginal tape: a prospective study of 313 consecutive patients. Neurourol Urodyn 2004; 23: Bhargava S and Chapple CR: Rising awareness of the complications of synthetic slings. Curr Opin Urol 2004; 14: 317.
Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011
Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Treatment, Urinary Stress Incontinence, Transurethral Effective Date: 01/01/2012 Document: ARB0359 Revision Date: Code(s): 53860 Transurethral
More informationPeriurethral Bulking Agents for the Treatment of Urinary Incontinence. Original Policy Date
MP 7.01.14 Periurethral Bulking Agents for the Treatment of Urinary Incontinence Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationMedical Policy Title: Periurethral Bulking ARBenefits Approval: <Date>
Medical Policy Title: Periurethral Bulking ARBenefits Approval: Agents for the Treatment of Incontinence Effective Date: 01/01/2012 Document: ARB0279 Revision Date: Code(s): 51715 Endoscopic injection
More informationUrinary Incontinence. Biopolymer GmbH & Co.KG - Germany
Urinary Incontinence Treatment Options: 1. Physical Therapy: a conservative early stage treatment for UI, including pelvic floor muscles training known as Kegel exercise. 2. Medications: by means of pharmaceutical
More informationMEDICAL POLICY SUBJECT: BULKING AGENTS FOR TREATMENT OF URINARY OR FECAL INCONTINENCE. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BULKING AGENTS FOR (ARCHIVED DATE: 05/28/09-, EDITED DATE: 05/27/10, 05/19/11, 05/24/12, 05/23/13) PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific
More informationMACROPLASTIQUE IMPLANTS
UROPLASTY, INC. MACROPLASTIQUE IMPLANTS INSTRUCTIONS FOR USE UROPLASTY, INC. MACROPLASTIQUE IMPLANTS INSTRUCTIONS FOR USE CONTRAINDICATIONS FOR USE Macroplastique must not be used in patients with: Acute
More informationOperative Approach to Stress Incontinence. Goals of presentation. Preoperative evaluation: Urodynamic Testing? Michelle Y. Morrill, M.D.
Operative Approach to Stress Incontinence Goals of presentation Michelle Y. Morrill, M.D. Director of Urogynecology The Permanente Medical Group Kaiser, San Francisco Review preoperative care & evaluation
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Bulking Agents for the Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Injectable Bulking Agents for the Treatment of Urinary and
More informationMP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment of Urinary and
More informationTitle: Zuidex versus Contigen for Stress Urinary Incontinence. Date: May 30, 2007
Title: Zuidex versus Contigen for Stress Urinary Incontinence Date: May 30, 2007 Context and policy issues: Stress urinary incontinence (SUI) is the involuntary leakage of urine during exercise or movements
More informationClinical Policy: Urinary Incontinence Devices and Treatments
Clinical Policy: Reference Number: CP.MP.142 Last Review Date: 03/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description
More informationTransvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence
Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationCorporate Medical Policy
Corporate Medical Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal File Name: Origination: Last CAP Review: Next CAP Review: Last Review: injectable_bulking_agents_for_the_treatment_of_urinary_and_fecal_incontinence
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2014 Origination: 2/1994 Next Review: 6/2015 Policy Blue Cross and Blue Shield of Kansas
More informationNew approaches in the pharmacological treatment of stress urinary incontinence
International Journal of Gynecology and Obstetrics 86 Suppl. 1 (2004) S1 S5 New approaches in the pharmacological treatment of stress urinary incontinence Keywords: Stress urinary incontinence; Epidemiology;
More informationDuloxetine in women awaiting surgery
DOI: 1.1111/j.1471-528.6.879.x www.blackwellpublishing.com/bjog Review article H Drutz Ontario Power Generation Building, Toronto, Ontario, Canada Correspondence: Prof. Dr H Drutz, Mount Sinai Hospital,
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Last Review Status/Date: September 2015 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances that used to increase tissue bulk. They can be injected periurethrally
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence: the management of urinary incontinence in women 1.1 Short title Urinary incontinence 2 Background a) The National
More informationq7:480499_P0 6/5/09 10:23 AM Page 1 WHAT YOU SHOULD KNOW ABOUT YOUR DIAGNOSIS OF STRESS URINARY INCONTINENCE
493495.q7:480499_P0 6/5/09 10:23 AM Page 1 WHAT YOU SHOULD KNOW ABOUT YOUR DIAGNOSIS OF STRESS URINARY INCONTINENCE 493495.q7:480499_P0 6/5/09 10:23 AM Page 2 What is Stress Urinary Incontinence? Urinary
More informationMP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Surgery End Date: 08/19/2018 Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2017 Origination: 2/1994 Next Review: 6/2018 Policy Blue Cross and Blue Shield of Kansas
More informationRisk Factors of Voiding Dysfunction and Patient Satisfaction After Tension-free Vaginal Tape Procedure
J Korean Med Sci 2005; 20: 1006-10 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Risk Factors of Voiding Dysfunction and Patient Satisfaction After Tension-free Vaginal Tape Procedure
More informationName of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy #: 455 Latest Review Date: July 2014 Category: Surgery Policy Grade: B Background/Definitions: As a
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Last Review Status/Date: March 2017 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to
More informationMedical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence EFFECTIVE DATE:02 5 2013 POLICY LAST UPDATED: 12 18 2018 OVERVIEW Bulking agents are injectable substances
More informationINJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
FECAL INCONTINENCE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationProtocol. Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal (70119) Medical Benefit Effective Date: 07/01/15 Next Review Date: 05/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11,
More informationTreatment Outcomes of Tension-free Vaginal Tape Insertion
Are the Treatment Outcomes of Tension-free Vaginal Tape Insertion the Same for Patients with Stress Urinary Incontinence with or without Intrinsic Sphincter Deficiency? A Retrospective Study in Hong Kong
More informationA PATIENT GUIDE TO Understanding Stress Urinary Incontinence
A PATIENT GUIDE TO Understanding Stress Urinary Incontinence Q: What is SUI? A: Stress urinary incontinence is defined as the involuntary leakage of urine. The problem afflicts approximately 18 million
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationURINARY INCONTINENCE
Center for Continence Care and Pelvic Medicine What is urinary incontinence? URINARY INCONTINENCE Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only
More informationUrethral pressure measurement in stress incontinence: does it help?
Int Urol Nephrol (2009) 41:491 495 DOI 10.1007/s11255-008-9506-9 UROLOGY - ORIGINAL PAPER Urethral pressure measurement in stress incontinence: does it help? Bassem S. Wadie Æ Ahmed S. El-Hefnawy Received:
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
7.01.19 Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Section 7.0 Surgery Subsection Effective Date February 27, 2015 Original Policy Date February 27, 2015 Next Review
More informationThe Management of Female Urinary Incontinence. Part 1: Aetiology and Investigations
The Management of Female Urinary Incontinence Part 1: Aetiology and Investigations Dr Oseka Onuma Gynaecologist and Pelvic Reconstructive Surgeon 4 Robe Terrace Medindie SA 5081 Urinary incontinence has
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationW17: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October :00-18:00
W7: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October 204 4:00-8:00 Start End Topic Speakers 4:00 4:05 Introduction Sherif Mourad 4:05 4:20 Pathophysiology
More informationStress Incontinence. Susannah Elvy Urogynaecology CNS
Stress Incontinence Susannah Elvy Urogynaecology CNS Definitions Prevalence Assessment Investigation Treatment Surgery Men International Continence Society define as the complaint of any involuntary leakage
More informationI-STOP TOMS Transobturator Male Sling
I-STOP TOMS Transobturator Male Sling The CL Medical I-STOP TOMS sling for male stress urinary incontinence was developed in France where it is widely used and is the market leader. It is constructed with
More informationA Simplified Urinary Incontinence Score for the Evaluation of Treatment Outcomes
Neurourology and Urodynamics 19:127 135 (2000) A Simplified Urinary Incontinence Score for the Evaluation of Treatment Outcomes Asnat Groutz, Jerry G. Blaivas,* and Jarrod E. Rosenthal Weill Medical College,
More informationTension-free Vaginal Tape for Urodynamic Stress Incontinence
Long-term Results of Tension-free Vaginal Tape Insertion for Urodynamic Stress Incontinence in Chinese Women at Eight-year Follow-up: a Prospective Study YM CHAN MBBS, MRCOG, FHKAM (O&G), DCG, DCH, DFM,
More informationResolution of urge urinary incontinence with midurethral sling surgery in patients with mixed incontinence and low-pressure urethra
Gynecol Surg (2012) 9:427 432 DOI 10.1007/s10397-012-0735-7 ORIGINAL ARTICLE Resolution of urge urinary incontinence with midurethral sling surgery in patients with mixed incontinence and low-pressure
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationAn Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence
European Urology European Urology 48 (2005) 488 494 Female UrologyöIncontinence An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence Christopher R. Chapple
More informationEfficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study
Efficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study Yvonne KY CHENG MBChB, MRCOG William WK TO MBBS, M Phil, FRCOG, FHKAM (O&G) HX
More informationKey Words: urinary incontinence, suburethral slings
Evaluation of Transobturator Tension-Free Vaginal Tapes in the Surgical Management of Mixed Urinary Incontinence: 3-Year Outcomes of a Randomized Controlled Trial Mohamed Abdel-Fattah,*, Laura R. Hopper
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationAnatomical and Functional Results of Pelvic Organ Prolapse Mesh Repair: A Prospective Study of 105 Cases
International Journal of Clinical Urology 2018; 2(1): 20-24 http://www.sciencepublishinggroup.com/j/ijcu doi: 10.11648/j.ijcu.20180201.14 Anatomical and Functional Results of Pelvic Organ Prolapse Mesh
More informationImpact of the Midurethral Sling Procedure on Quality of Life in Women with Urinary Incontinence
www.kjurology.org DOI:10.4111/kju.2010.51.2.122 Voiding Dysfunction Impact of the Midurethral Sling Procedure on Quality of Life in Women with Urinary Incontinence Hwa Su Lim, Jong Min Kim, Phil Hyun Song,
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationUrodynamic findings in women with insensible incontinence
bs_bs_banner International Journal of Urology (2013) 20, 429 433 doi: 10.1111/j.1442-2042.2012.03146.x Original Article: Clinical Investigation Urodynamic findings in women with insensible Benjamin M Brucker,
More informationDuloxetine, a Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) for the Treatment of Stress Urinary Incontinence: A Systematic Review
european urology 51 (2007) 67 74 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Female Urology Incontinence Duloxetine, a Serotonin and Noradrenaline Reuptake Inhibitor
More informationComparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents
Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents Abstract Andrew J. Steward Department of Aerospace and Mechanical Engineering University of Notre Dame, Notre Dame, IN
More informationEffect of Anesthesia on Voiding Function After Tension-Free Vaginal Tape Procedure
Effect of Anesthesia on Voiding Function After Tension-Free Vaginal Tape Procedure M. Murphy, MD, M. H. Heit, MD, MSPH, L. Fouts, MD, C. A. Graham, MD, L. Blackwell, RN, and P. J. Culligan, MD OBJECTIVE:
More informationChristopher F. Maher, a Barry A. O Reilly, a Peter L. Dwyer, a Marcus P. Carey, a Anne Cornish, a Philip Schluter b
BJOG: an International Journal of Obstetrics and Gynaecology June 2005, Vol. 112, pp. 797 801 DOI: 10.1111/j.1471-0528.2005.00547.x ubovaginal sling versus transurethral for stress urinary incontinence
More informationPolyacrylamide Hydrogel (Bulkamid ) in Female Patients of 80 or More Years with Urinary Incontinence
ORIGINAL ARTICLE Vol. 40 (1): 37-43 January - February, 2014 doi: 10.1590/S1677-5538.IBJU.2014.01.06 Polyacrylamide Hydrogel (Bulkamid ) in Female Patients of 80 or More Years with Urinary Incontinence
More informationA minimally invasive treatment for stress urinary incontinence
A minimally invasive treatment for stress urinary incontinence This booklet provides information about the Bulkamid hydrogel for the treatment of stress urinary incontinence What is stress urinary incontinence?
More informationBlue Ridge Urogynecology
Surgery for Stress Urinary Incontinence Surgery has proved to be a very effective treatment for stress incontinence. The best surgical procedures improve or cure the incontinence in 85 to 90 percent of
More informationInterventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566
Single-incision short sling mesh insertion for stress urinary incontinence in women Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Your responsibility This guidance
More informationAdvanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa
Advanced Care for Female Overactive Bladder & Urinary Incontinence Department of Urology Kaiser Permanente Santa Rosa Goals Participants will: Review normal urinary tract anatomy and function Understand
More informationSep \8958 Appell Dmochowski.ppt LMF 1
Surgical Outcomes (How did we get ourselves into this mess?) Roger R. Dmochowski, MD, FACS Department of Urologic Surgery Vanderbilt University School of Medicine Nashville, Tennessee Considerations Evaluation
More informationThis information is intended as an overview only
This information is intended as an overview only Please refer to the INSTRUCTIONS FOR USE included with this device for indications, contraindications, warnings, precautions and other important information
More informationCorporate Medical Policy
Corporate Medical Policy Vesicoureteral Reflux, Treatment with Periureteral Bulking Agents File Name: Origination: Last CAP Review: Next CAP Review: Last Review: vesicoureteral_reflux_treatment_with_periureteral_bulking_agents
More informationLong-Term Durability of the Distal Urethral Polypropylene Sling for the Treatment of Stress Urinary Incontinence: Minimum 11-Year Followup
Long-Term Durability of the Distal Urethral Polypropylene Sling for the Treatment of Stress Urinary Incontinence: Minimum 11-Year Followup Lisa Rogo-Gupta,*, Z. Chad Baxter, Ngoc-Bich Le, Shlomo Raz and
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More information6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence
6 Page Male Incontinence Booklet /9/ :44 Page The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page Stress Urinary Incontinence - A Stressful Prospect
More informationJohn Laughlin 4 th year Cardiff University Medical Student
John Laughlin 4 th year Cardiff University Medical Student Prolapse/incontinence You need to know: Pelvic floor anatomy in relation to uterovaginal support and continence The classification of uterovaginal
More informationProlapse & Urogynaecology. Hester Mannion and Fabi Sica
Prolapse & Urogynaecology Hester Mannion and Fabi Sica Take home messages Prolapse and associated incontinence is very common It has a devastating effect on the QoL of the patient and their partner Strategies
More informationMedical Policy. Description/Scope. Position Statement
Subject: Document #: Current Effective Date: 03/29/2017 Status: Revised Last Review Date: 02/02/2017 Description/Scope This document addresses the following treatments for urinary incontinence: Vaginal
More informationAutologous Muscle Derived Cells for Treatment of Stress Urinary Incontinence in Women
Autologous Muscle Derived Cells for Treatment of Stress Urinary Incontinence in Women Kenneth M. Peters,* Roger R. Dmochowski, Lesley K. Carr, Magali Robert, Melissa R. Kaufman, Larry T. Sirls,k Sender
More informationMedical Review Criteria Invasive Treatment for Urinary Incontinence
Medical Review Criteria Invasive Treatment for Urinary Incontinence Effective Date: December 21, 2016 Subject: Invasive Treatment for Urinary Incontinence Background: Urinary incontinence (the involuntary
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationLoss of Bladder Control
BLADDER HEALTH: Surgery for Urinary Incontinence Loss of Bladder Control Surgery for Urinary Incontinence Don t Let Urinary Incontinence Keep You from Enjoying Life. What is Urinary Incontinence? What
More informationWhat you should know about your diagnosis of incontinence
What you should know about your diagnosis of incontinence What is Stress Urinary Incontinence? WHAT IS NORMAL URINARY FUNCTION? Urine is a normal waste product of the body that is manufactured by the kidneys
More informationOutcomes of Midurethral Slings in Women with Concomitant Preoperative Severe Lower Urinary Tract Voiding Symptoms
ORIGINAL RESEARCH The Ochsner Journal 15:223 227, 2015 Ó Academic Division of Ochsner Clinic Foundation Outcomes of Midurethral Slings in Women with Concomitant Preoperative Severe Lower Urinary Tract
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationUrinary Incontinence
Urinary Incontinence Q: What is urinary incontinence and what causes it? A: When you are not able to hold your urine until you can get to a bathroom, you have what s called urinary incontinence (also called
More informationUrodynamics in women. Aims of Urodynamics in women. Why do Urodynamics?
Urodynamics in women Chendrimada Madhu MD, MA, MRCOG Subspecialty Trainee in Urogynaecology Southmead Hospital 2013 Aims of Urodynamics in women n Confirmation of incontinence and its cause n Definition
More informationSequential Assessment of Urodynamic Findings before and aftertension-free Vaginal Tape (TVT) Operation for Female Genuine Stress Incontinence
European Urology European Urology 45 (2004) 362 366 Sequential Assessment of Urodynamic Findings before and aftertension-free Vaginal Tape (TVT) Operation for Female Genuine Stress Incontinence Long-Yau
More informationBard: Continence Therapy. Stress Urinary Incontinence. Regaining Control. Restoring Your Lifestyle.
Bard: Continence Therapy Stress Urinary Incontinence Regaining Control. Restoring Your Lifestyle. Stress Urinary Incontinence Urinary incontinence is a common problem and one that can be resolved by working
More informationSAFYRE TM : A READJUSTABLE MINIMALLY INVASIVE SLING FOR FEMALE URINARY STRESS INCONTINENCE
Urological Neurology International Braz J Urol Official Journal of the Brazilian Society of Urology SAFYRE TM - SLING FOR FEMALE SUI Vol. 29 (4): 353-359, July - August, 2003 SAFYRE TM : A READJUSTABLE
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationLatest Treatments for a Leaky Bladder None
Latest Treatments for a Leaky Bladder None Financial Disclosures Jeremiah McNamara, MD, OBGYN Boulder Women s Care 303-500-1947 Boulder Women s Care Agenda: Prolapse & Urinary Incontinence The Pelvic Floor
More informationIncontinence: The silent scourge of the young and old. The International Continence Society has. In this article:
Focus on CME at the University of Toronto Incontinence: The silent scourge of the young and old By Sender Herschorn, BSc, MDCM, FRCSC In this article: 1. What is the workup for urinary incontinence? 2.
More informationVoiding Diary. Begin recording upon rising in the morning and continue for a full 24 hours.
Urodvnamics Your physician has scheduled you for a test called URODYNAMICS. This test is a series of different measurements of bladder function and can be used to determine the cause of a variety of bladder
More informationManagement of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital
Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence
More informationDraft Guidance for Industry and FDA Staff Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence
Draft Guidance for Industry and FDA Staff Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationSubject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
09-A9000-03 Original Effective Date: 02/15/12 Reviewed: 12/06/18 Revised: 12/15/18 Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence THIS MEDICAL COVERAGE GUIDELINE
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationCurrent Role of Urethrolysis and Partial Excision in Patients Seeking Revision of Anti-Incontinence Sling
ORIGINAL ARTICLE Current Role of Urethrolysis and Partial Excision in Patients Seeking Revision of Anti-Incontinence Sling Alice Drain, MD,* Ekene Enemchukwu, MD, MPH, Nihar Shah, BA,* Raveen Syan, MD,*
More informationIncidence and Risk Factors of Postoperative De Novo Voiding Dysfunction following Midurethral Sling Procedures
Incidence and Risk Factors of Postoperative De Novo Voiding Dysfunction following Midurethral Sling Procedures Hoon Ah Jang, Jae Hyun Bae, Jeong Gu Lee From the Department of Urology, College of Medicine,
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationAdVance Male Sling System
AdVance Male Sling System Clinical study summary This document is a compilation and summary of several AdVance Male Sling System peer-reviewed journal articles. The information presented here is taken
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More information*Please see amendment for Pennsylvania Medicaid at the end
1 of 90 Number: 0223 (Replaces CPBs 283, 324, and 470) Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. I. Aetna considers multi channel urodynamic studies medically necessary
More informationAccess to the published version may require journal subscription. Published with permission from: Blackwell
This is an author produced version of a paper published in Acta Obstetricia et Gynecologica Scandinavica. This paper has been peer-reviewed but does not include the final publisher proof-corrections or
More information